Evotec SE
EVT: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€2.10 | Jbph | Zqtztjjg |
Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive
Business Strategy and Outlook
Evotec is a drug discovery partnership firm that has a contract development and manufacturing organization, or CDMO, business, in addition to an innovative drug development program focused on collaboration with clients. The firm offers services across a variety of therapeutic areas and serves a diverse client base of large and midsize pharmaceutical and biotechnology companies. Following a recent period of investment that has weighed on returns, Evotec appears well positioned to mature and stabilize its business as its strategic growth initiatives materialize.